{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
alpha-tocopherol acetate
to a specific field?
Status:
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Investigational
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
HU-308 ([(1R,2R,5R)-2-[2,6-dimethoxy-4-(2-methyloctan-2-yl)phenyl]-7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl]methanol) is a potent, selective agonist for the CB2 receptor. The synthesis and characterization took place in the laboratory of Prof. Mechoulam at the Hebrew University of Jerusalem in the late 1990s. It has analgesic effects, promotes proliferation of neural stem cells,[3] and protects both liver and blood vessel tissues against oxidative stress via inhibition of TNF-α. In vivo, HU-308 has hypotensive, analgesic, and anti-inflammatory activities in mice that can be reversed by the CB2 receptor antagonist SR 144528 but not the CB1 receptor antagonist rimonabant. Pretreatment of mice with HU-308 decreases the I/R-induced tissue damage, inflammatory cell infiltration, tissue, and serum TNF-α, MIP-1, and MIP-2 levels, tissue lipid peroxidation, and apoptosis. HU-308 increases proliferation of HT29 colon cancer cells and growth of tumors in an HT29 mouse xenograft model. The physiological and toxicological properties of this compound have not been evaluated in humans.
Status:
Investigational
Source:
NCT02764385: Not Applicable Interventional Completed Smoking
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT03820245: Not Applicable Interventional Completed Oxidative Stress
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Class (Stereo):
CHEMICAL (ABSOLUTE)
LAPISTERIDE is an inhibitor of 5alpha-reductase (5aR), converting testosterone to the more potent androgen dihydrotestosterone. It has dual inhibitory activity on both 5aR isoenzymes. It was under investigation for the treatment of benign prostatic hyperplasia and androgenic alopecia, but its development was discontinued.
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Conditions:
Imiloxan is a highly selective alpha2B adrenoceptor antagonist and was developed for depression in the 1980s. In Phase 1 clinical trials imiloxan dosing led to hypersensitivity reactions; the molecule's development was discontinued.
Class (Stereo):
CHEMICAL (ABSOLUTE)
LASINAVIR, a hydroxyethylene derivative, is highly specific human immunodeficiency virus (HIV) protease inhibitor with an IC50 of 1 nM. Its clinical development was discontinued.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Nupafant (BB-960) is a potent platelet activating factor antagonist that is active both orally and intravenously. Nupafant was in phase I clinical trials in the UK for the treatment of ischemia-reperfusion injury, however this compound has since been suspended.
Status:
Investigational
Source:
INN:difencloxazine [INN]
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Difencloxazine is a tranquilizing agent.
Status:
Investigational
Source:
NCT01399164: Not Applicable Interventional Completed Vitamin B-12 Deficiency
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Entasobulin (ZEN-012; AEZS-112) is a small molecule with several mechanisms of action, such as DNA fragmentation via inhibition of topoisomerase II as well as inhibition of tubulin polymerization. It exerts antineoplastic activity. It was being developed for the treatment of cancers.
